Advanced search
Publication Cover
Leukemia & Lymphoma Volume 52, 2011 - Issue 2
Submit an article Journal homepage
164
Views
3
CrossRef citations to date
0
Altmetric
Original Articles: Clinical

Plasma cell labeling index correlates with deletion of 13q14 in multiple myeloma

Chunming LiDepartment of Hematology, the First Affiliated Hospital of Nanjing Medical University, Jiangsu Province Hospital, Nanjing, China
,
Lijuan ChenDepartment of Hematology, the First Affiliated Hospital of Nanjing Medical University, Jiangsu Province Hospital, Nanjing, ChinaCorrespondence[email protected]
,
Xiao GaoDepartment of Hematology, the First Affiliated Hospital of Nanjing Medical University, Jiangsu Province Hospital, Nanjing, China
,
Xiaoyan QuDepartment of Hematology, the First Affiliated Hospital of Nanjing Medical University, Jiangsu Province Hospital, Nanjing, China
,
Wenyi ShenDepartment of Hematology, the First Affiliated Hospital of Nanjing Medical University, Jiangsu Province Hospital, Nanjing, China
,
Ruifang YangDepartment of Hematology, the First Affiliated Hospital of Nanjing Medical University, Jiangsu Province Hospital, Nanjing, China
,
Run ZhangDepartment of Hematology, the First Affiliated Hospital of Nanjing Medical University, Jiangsu Province Hospital, Nanjing, China
,
Hairong QiuDepartment of Hematology, the First Affiliated Hospital of Nanjing Medical University, Jiangsu Province Hospital, Nanjing, China
,
Jiaren XuJiangsu Province Institute of Geriatrics, Nanjing, China
,
Hua LuDepartment of Hematology, the First Affiliated Hospital of Nanjing Medical University, Jiangsu Province Hospital, Nanjing, China
&
Jianyong LiDepartment of Hematology, the First Affiliated Hospital of Nanjing Medical University, Jiangsu Province Hospital, Nanjing, China
 show all
Pages 260-264 | Received 25 Aug 2010, Accepted 04 Nov 2010, Published online: 06 Dec 2010

References

  • Barlogie B, Kyle RA, Anderson KC, et al. Standard chemotherapy compared with high-dose chemotherapy for multiple myeloma: final results of phase III US Intergroup Trial S9321. J Clin Oncol 2006;24:929–936.
  • Fonseca R, Barlogie B, Bataille R, et al. Genetics and cytogenetics of multiple myeloma: a workshop report. Cancer Res 2004;64:1546–1558.
  • Steensma DP, Gertz MA, Greipp PR, et al. A high bone marrow plasma cell labeling index in stable plateau-phase multiple myeloma is a marker for early disease progression and death. Blood 2001;97:2522–2523.
  • Rajkumar SV, Fonseca R, Dewald GW, et al. Cytogenetic abnormalities correlate with the plasma cell labeling index and extent of bone marrow involvement in myeloma. Cancer Genet Cytogenet 1999;113:73–77.
  • Hardan I, Rothman R, Gelibter A, et al. Determination of chromosome 13 status in bone marrow cells of patients with multiple myeloma using morphologic and fluorescence in situ hybridization analysis. Exp Hematol 2004;32:254–260.
  • Chen L, Li J, Xu W, et al. Molecular cytogenetic aberration in patients with multiple myeloma studied by interphase fluorescence in situ hybridization. Exp Oncol 2007;29:116–120.
  • Greipp PR, Lust JA, O'Fallon WM, Katzmann JA, Witzig TE, Kyle RA. Plasma cell labeling index and beta 2-microglobulin predict survival independent of thymidine kinase and C-reactive protein in multiple myeloma. Blood 1993;81:3382–3387.
  • Kröger N, Schilling G, Einsele H, et al. Deletion of chromosome band 13q14 as detected by fluorescence in situ hybridization is a prognostic factor in patients with multiple myeloma who are receiving allogeneic dose-reduced stem cell transplantation. Blood 2004;103:4056–4061.
  • Schambeck CM, Bartl R, Höchtlen-Vollmar W, Wick M, Lamerz R, Fateh-Moghadam A. Characterization of myeloma cells by means of labeling index, bone marrow histology, and serum β2-microglobulin. Am J Clin Pathol 1996;106:64–68.
  • Chng WJ, Glebov O, Bergsagel PL, Kuehl WM. Genetic events in the pathogenesis of multiple myeloma. Best Pract Res Clin Haematol 2007;20:571–596.
  • Bergsagel PL, Kuehl WM. Molecular pathogenesis and a consequent classification of multiple myeloma. J Clin Oncol 2005;23:6333–6338.
  • Schmidt-Wolf IG, Glasmacher A, Hahn-Ast C, et al. Chromosomal aberrations in 130 patients with multiple myeloma studied by interphase FISH: diagnostic and prognostic relevance. Cancer Genet Cytogenet 2006;167:20–25.
  • Gertz MA, Lacy MQ, Dispenzieri A, et al. Clinical implications of t(11;14)(q13;q32), t(4;14)(p16.3;q32), and -17p13 in myeloma patients treated with high-dose therapy. Blood 2005;106:2837–2840.
  • Zojer N, Königsberg R, Ackermann J, et al. Deletion of 13q14 remains an independent adverse prognostic variable in multiple myeloma despite its frequent detection by interphase fluorescence in situ hybridization. Blood 2000;95:1925–1930.
  • Keats JJ, Reiman T, Belch AR, Pilarski LM. Ten years and counting: so what do we know about t(4;14)(p16;q32) multiple myeloma. Leuk Lymphoma 2006;47:2289–2300.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Order Reprints Request Corporate Permissions

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

Request Academic Permissions

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.